Nasal epithelial cells maintain eosinophil survival by secreting granulocyte/macrophage colony-stimulating factor (GM-CSF). Corticosteroids antagonize eosinophil viability induced by GM-CSF. We investigated the eect of topical corticosteroids and nedocromil sodium on the release of GM-CSF from nasal polyp epithelial cells.
Introduction
There is evidence that the eosinophil in®ltrate in nasal polyps is the consequence of both preferential recruitment of eosinophils (1, 2) and prolonged eosinophil survival within the in¯amed microenvironment (3, 4) .
Epithelial cells synthesize a number of growth factors and cytokines (5) . Among other potential cytokines, nasal epithelial cells maintain eosinophil survival by secreting granulocyte/macrophage colony-stimulating factor (GM-CSF) (2, 3, 4) . Corticosteroids antagonize the viabilitysustaining eect of GM-CSF (3, 4) .
Topical corticosteroids are the recommended treatment for patients with nasal polyposis (6) . Nasal polyp epithelial cells are the ®rst line target for topical corticosteroids. In this study we focused on the eect of topical corticosteroids on GM-CSF because of the important role of this cytokine in eosinophil survival. We hypothesize that topical corticosteroid potency should be related to their capacity to inhibit the release of GM-CSF.
Methods

SUBJECTS
Nasal polyps were obtained from 19 patients (12 men, seven women), aged 50 2 years, undergoing nasal polypectomy. Seventeen patients (90%) were on intranasal or oral corticosteroids at the time polypectomy was carried out. The study was approved by the Ethics Committee of our Institution.
EPITHELIAL CELL CULTURE
Transport of nasal polyps, and isolation, characterization and culture of epithelial cells, were carried out according to a method previously described in detail (3). After reaching con¯uence, cultured epithelial cells were incubated with 10% foetal calf serum (FCS, Flow laboratories) for 48 h in the absence (control) and presence of budesonide (Astra, Barcelona, Spain),¯uticasone propionate (Glaxo Wellcome, Greenford, U.K.), beclomethasone dipropionate (Glaxo Wellcome, Greenford, U.K.), triamcinolone acetonide (Sigma, Spain) and nedocromil sodium (Fisons IbeÂ rica, Zaragoza, Spain). Dose-response curves were obtained using concentrations from 10 75 to 10 713 M.
GM-CSF PRODUCTION
GM-CSF concentration in the cell supernatants was directly measured by a commercial enzymo-linked immunoassay using a`sandwich' technique (Amersham IbeÂ rica, Spain). GM-CSF limit of detection was 4 pg/ml. 
STATISTICAL ANALYSIS
Results
Incubation of nasal polyp epithelial cells with 10% FCS increased GM-CSF production in all experiments. At baseline, the range of GM-CSF secretion was 26±89 pg ml 71 while after 10% FCS stimulation was 213±684 pg ml 71 . FCS-induced release of GM-CSF was inhibited in a dose-dependent manner by all four topical corticosteroids. The inhibitory eects at 10 75 M concentration were: uticasone propionate 71% (n=6, P50Á01), budesonide 58% (n=7, P50Á01), triamcinolone acetonide 42% (n=6, P50Á02) and beclomethasone dipropionate 40% (n=6, P50Á02), compared to positive control (10% FCS-treated cells).
The ( Fig. 1) . Nedocromil sodium at 10 75 M did not have a signi®cant inhibitory eect on GM-CSF production (10%, n=6).
The potencies of the four corticosteroids on GM-CSF release were compared. Table 1 shows the concentration of corticosteroids producing 25% inhibition (IC 25 ) of GM-CSF release. We used IC 25 instead of IC 50 because most corticosteroids did not reach 50% inhibition of the FCSinduced GM-CSF production. Fluticasone propionate was the most potent inhibitor of GM-CSF release, and was signi®cantly more potent than budesonide. Both¯uticasone propionate and budesonide were more potent than beclomethasone dipropionate and triamcinolone acetonide. All glucocorticoids were more potent than nedocromil sodium.
Discussion
In this study we investigated the ability of several topical corticosteroids and nedocromil sodium to modulate the release of GM-CSF from nasal polyp epithelial cells in vitro. However, the role of other cytokines produced by epithelial and other cells, such as IL-5 and eotaxin, which are potent eosinophil modulators should not be overlooked.
The eect of topical corticosteroids on GM-CSF release from nasal polyp epithelial cells has signi®cance because previous studies have shown that GM-CSF is responsible for the induction of eosinophil survival (3, 4) . The chronic presence of eosinophils in the respiratory mucosa results in epithelial damage caused by cytotoxic products released by degranulated cells. By reducing eosinophil viability, topical corticosteroids contribute to reduce in¯ammation and therefore facilitate mucosal damage repair. In this regard, Kanai et al. (7) have shown the ecacy of budesonide in reducing the number of activated eosinophil in nasal polyps.
Our in vitro assay of topical corticosteroid potency tested four topical corticosteroids for their capacity to inhibit the release of GM-CSF from nasal polyp epithelial cells. The comparison study showed that¯uticasone propionate is the most potent, followed by budesonide, beclomethasone dipropionate and triamcinolone acetonide. Nedocromil sodium had no eects on GM-CSF secretion.
The rank of potency found in our study closely agrees with the rank order and relative potency obtained with the same corticosteroids using the classical skin blanching method. With this method the potency of¯uticasone was 1200 (relative to the potency of dexamethasone, considered 1), budesonide 980, beclomethasone dipropionate 600 and triamcinolone acetonide 330 (8) .
Ideally, the validity of results obtained in in vitro studies should be reproduced in in vivo surveys. Long-term treatment with topical corticosteroids has been shown to reduce symptoms of nasal polyposis and reduce polyp recurrence following surgery (9±11). However, only a few clinical trials have compared the clinical response of nasal polyposis to dierent corticosteroids.
Two recent studies compared¯uticasone propionate and beclomethasone dipropionate in patients with severe polyposis (12, 13) . In the two studies there was evidence that patients treated with¯uticasone propionate responded faster, and that the magnitude of the response was greater than in patients receiving beclomethasone dipropionate. Although our in vitro model may have some limitations in relation to the presence of a constant steroid concentration, the absence or decrease of metabolism, and the potential lack of active metabolite formation, for instance beclomethasone 17-monopropionate from beclomethasone dipropionate, the present in vitro model may be used as a useful method to investigate and compare the potency of topical anti-in¯ammatory drugs.
Although previous studies have shown that nedocromil sodium signi®cantly prevents stimulated GM-CSF production in both cultured human bronchial (14) and nasal epithelial cells (15), we could not ®nd any signi®cant eect of this drug on GM-CSF release from cultured nasal polyp epithelial cells. This ®nding suggests that the in¯amed microenvironment of nasal polyps had induced a relative resistance to the pharmacological activity of nedocromil sodium in epithelial cells. To our knowledge, nedocromil sodium has not been used in the treatment of nasal polyposis. However, our results predict poor clinical results for this drug in the treatment of nasal polyps.
In summary, our study suggests that topical steroids may reduce eosinophil in®ltration in nasal polyps by downregulating the production of epithelial cell-derived cytokines, such as GM-CSF, which prolongs eosinophil viability. Quantitatively, the following rank of potency was observed:¯uticasone propionate 4 budesonide 4 beclomethasone dipropionate 4 triamcinolone acetonide 44 nedocromil sodium. 
